Document Detail

Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?
Jump to Full Text
MedLine Citation:
PMID:  22744819     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Approximately 10% of patients clinically diagnosed with early Parkinson's disease (PD) subsequently have normal dopaminergic functional imaging. Transcranial sonography (TCS) has been shown to detect midbrain hyperechogenicity in approximately 90% of Parkinson's disease (PD) patients and 10% of the healthy population. The aim of this study was to investigate the prevalence of midbrain hyperechogenicity in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDD), in comparison to PD patients.
METHODS: TCS was performed in 14 patients with SWEDD and 19 PD patients.
RESULTS: There was a significantly increased area of echogenicity in the PD group (0.24 ± 0.06 cm(2) ), compared to the group of patients with SWEDD (0.13 ± 0.06 cm(2) ; P < 0.001). One (9.1%) of these patients, compared to 14 (82.5%) of the PD patients, was found to have hyperechogenicity (P < 0.001).
CONCLUSIONS: We conclude that TCS is useful to distinguish PD patients from patients with suspected parkinsonism and SWEDD.
Authors:
Heike Stockner; Petra Schwingenschuh; Atbin Djamshidian; Laura Silveira-Moriyama; Petra Katschnig; Klaus Seppi; John Dickson; Mark J Edwards; Andrew J Lees; Werner Poewe; Kailash P Bhatia
Related Documents :
21792729 - Mibg scintigraphy in differential diagnosis of parkinsonism: a meta-analysis.
15794669 - Association of mild transient elevation of troponin i levels with increased mortality a...
19468209 - High stable serum adiponectin levels are associated with a better outcome in prevalent ...
20639239 - Serum bilirubin predicts long-term clinical outcomes in patients with cardiac syndrome x.
9852879 - Effect of payer status on outcomes of coronary artery bypass surgery in blacks.
25364549 - The correlation between electroencephalography amplitude and interictal abnormalities: ...
22415199 - Microalterations of esophagus in patients with non-erosive reflux disease: in-vivo diag...
21991169 - Sperm quality changes in survivors of severe burns.
2272059 - Management of survivors of out-of-hospital cardiac arrest.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-06-28
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  27     ISSN:  1531-8257     ISO Abbreviation:  Mov. Disord.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-08-06     Completed Date:  2012-12-17     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1182-5     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Movement Disorder Society.
Affiliation:
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria. heike.stockner@i-med.ac.at
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Cognition Disorders / complications
Diagnosis, Differential
Dopamine / metabolism*
Female
Humans
Magnetic Resonance Imaging
Male
Mesencephalon / radionuclide imaging,  ultrasonography
Middle Aged
Nerve Fibers, Myelinated
Neuropsychological Tests
Parkinson Disease / physiopathology*,  radionuclide imaging,  ultrasonography*
Positron-Emission Tomography
Temporal Bone / ultrasonography
Ultrasonography, Doppler, Transcranial / methods*
Grant Support
ID/Acronym/Agency:
089698//Wellcome Trust
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Mov Disord
Journal ID (iso-abbrev): Mov. Disord
Journal ID (publisher-id): mds
ISSN: 0885-3185
ISSN: 1531-8257
Publisher: Wiley Subscription Services, Inc., A Wiley Company, Hoboken
Article Information
Download PDF
Copyright © 2012 Movement Disorder Society
open-access:
Received Day: 20 Month: 7 Year: 2011
Revision Received Day: 22 Month: 5 Year: 2012
Accepted Day: 04 Month: 6 Year: 2012
Print publication date: Month: 8 Year: 2012
Electronic publication date: Day: 28 Month: 6 Year: 2012
Volume: 27 Issue: 9
First Page: 1182 Last Page: 1185
PubMed Id: 22744819
ID: 3660780
DOI: 10.1002/mds.25102

Is Transcranial Sonography Useful to Distinguish Scans Without Evidence of Dopaminergic Deficit Patients From Parkinson's Disease?
Heike Stockner, MD1*
Petra Schwingenschuh, MD23
Atbin Djamshidian, MD4
Laura Silveira-Moriyama, MD4
Petra Katschnig, MD23
Klaus Seppi, MD1
John Dickson, PhD5
Mark J Edwards, PhD2
Andrew J Lees, MD4
Werner Poewe, MD1
Kailash P Bhatia, MD2
1Department of Neurology, Medical University InnsbruckInnsbruck, Austria
2Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London (UCL)London, United Kingdom
3Department of Neurology, Division of Special Neurology, Medical University of GrazGraz, Austria
4Reta Lila Weston Institute of Neurological Studies, UCL, Institute of NeurologyLondon, United Kingdom
5Institute of Nuclear Medicine, UCLLondon, United Kingdom
Correspondence: *Correspondence to: Dr. Heike Stockner, Department of Neurology, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria; heike.stockner@i-med.ac.at
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.

Recent clinical trials using [123I]β-CIT single-photon emission computed tomography (SPECT) and [18F]-dopa PET as surrogate markers for disease progression have found that 5.7% to 14.7% of cases clinically diagnosed as early Parkinson's disease (PD) have normal scans (scans without evidence of dopaminergic deficit; SWEDD).1, 2 In a European multicenter prospective study including diagnostically uncertain cases and performing FP-CIT-SPECT, the rate of SWEDD was 21%.3 The proportion of SWEDD in general practice is currently unknown, and the significance of normal imaging in patients with a clinical diagnosis of PD is still debated. There is growing evidence that these patients suffer from conditions not affecting the nigrostriatal dopaminergic system and may therefore have different pathophysiology, prognosis, and treatment requirements. SWEDD subjects in the ELLDOPA study lacked clinical responsiveness to levodopa,4 and follow-up dopamine transporter (DAT) scans after 4 years remained normal.5 Recently, it was shown that abnormality in cortical plasticity, assessed by paired associative stimulation, was markedly different in PD and tremulous SWEDD.6 Alternative diagnoses have been considered as essential tremor (ET), depression, vascular or psychogenic parkinsonism, dopa-responsive dystonia, supranigral parkinsonism,4 and primary adult-onset dystonic tremor.79

Certain clinical features point toward a diagnosis of tremulous SWEDD, such as lack of true bradykinesia and presence of dystonia or head tremor, whereas reemergent tremor, true fatiguing or decrement, good response to dopaminergic drugs, and the presence of nonmotor symptoms favor a diagnosis of PD.6, 10, 11 However, clinical distinction of tremulous SWEDD from PD remains difficult in some cases.12

Hyperechogenic alterations in the area of the midbrain have been consistently found in up to 90% of patients with PD in a variety of studies using transcranial sonography (TCS).1315 Midbrain hyperechogenicity has also been observed in approximately 10% of the healthy population. Recent studies have suggested an increased risk of developing PD in a subgroup of people with midbrain hyperechogenicity.16, 17 In addition, midbrain hyperechogenicity has been associated with the development of PD in patients with idiopathic REM sleep behavior disorder.18, 19

In the present study, we aimed to investigate the prevalence of midbrain hyperechogenicity in SWEDD, in comparison to patients with PD.


Patients and Methods

The study received approval from the local ethics committees and conformed to the Declaration of Helsinki. All participants gave written informed consent.

Subjects

Of a total of 34 SWEDD patients observed between April 2007 and September 2009 in two movement disorder centers, 14 agreed to participate in the present study (8 from the Department of Neurology, University College London [UCL; London, UK] and 6 from the Department of Neurology, Medical University Innsbruck [Innsbruck, Austria]). All had a clinical suspected diagnosis of PD made by a neurologist and a subsequent normal DAT-SPECT scan ([123I]FP-CIT: n = 11; [123I]ß-CIT: n = 3). We additionally recruited 19 consecutive patients with a diagnosis of PD according to UK Brain Bank Criteria and abnormal [123I]FP-CIT SPECT scans. Striatal FP-CIT uptake was quantified by measuring the striatal/posterior lobe binding. Striatal binding of [123I]FP-CIT (putaminal binding of [123I]ß-CIT) was considered normal when the absolute tracer accumulation was >2.5 (>7.8) or the side-to-side difference of [123I]FP-CIT was >0.15. In both centers, patients with SWEDD had normal scans, as defined by the criteria above.20, 21

Demographic and clinical data of patients are summarized in Table 1.

Sonography

TCS was performed using a 2.5-MHz transducer (Logiq 7; General Electric, Milwaukee, WI) from both sides using the acoustic temporal bone window. All SWEDD and PD patients were examined by the same experienced sonographer (H.S.) who was blinded to the diagnosis. TCS was performed in a random order and patients were lying in the supine position, covered with a blanket up to the neck, before the blinded investigator entered the darkened room. For analysis, only subjects were included for whom the typical butterfly-shaped mesencephalon was clearly displayed. Images of TCS examinations were stored digitally and were used for the segmentation procedure, as described previously.13, 18

To compare areas of echogenicity and the prevalence of hyperechogenicity between groups, the side of the midbrain with the greater area of echogenicity (right or left) of each subject was used for statistical comparison between groups. Hyperechogenicity of the area of SN was defined as an area of echogenic signal of 0.20 cm2 or greater on at least one side. This value corresponds to the 90th percentile of the area of echogenicity in the SN region of a population-based cohort of healthy individuals 50 years of age and above, who had been investigated by the same TCS examiner (H.S.), as described previously.18

Statistical Analysis

Data were tabulated and analyzed using SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL). Because echogenic areas of the SN were not normally distributed, as demonstrated by Shapiro-Wilks' test, Mann-Whitney's U test was applied for statistical comparisons of areas of echogenic signals in the SN between groups. Group comparison of the prevalence of hyperechogenic signal in the SN region was performed by the chi-square test for categorical variables. Between comparisons were performed with two-tailed unpaired t tests and Fisher's exact tests. The significance level was set at P < 0.05. Results are reported as means ± standard deviation (SD; median). In addition, the diagnostic accuracy of midbrain hyperechogenicity for the diagnosis of PD was calculated.


Results

Seventeen (89.5%) PD patients and 11 (78.5%) SWEDD patients had a sufficient acoustic temporal bone window for TCS investigation. No significant difference of area of echogenic signal was found between male and female subjects in either group. There was a significantly increased area of echogenicity in the SN region in the PD group, compared to the SWEDD group (P < 0.001). Mean size of echogenic area of SWEDD patients was 0.13 ± 0.06 cm2 (median, 0.14), compared to 0.24 ± 0.06 cm2 (median, 0.25) in patients with PD (P < 0.001) (see Fig. 1). One SWEDD patient (9.1%) was found to have midbrain hyperechogenicity defined as an area of echogenic signal of 0.20 cm2 or greater on at least one side, as compared to 14 (82.5%) of the PD patients (P < 0.001).

For diagnostic accuracy of midbrain hyperechogenicity for the differential diagnosis of PD versus SWEDD, see Table 1.


Discussion

The clinical diagnosis of PD can be challenging in the early stage and when patients present with subtle or ambiguous signs.

In a number of studies, midbrain hyperechogenicity in the area of the SN has been a consistent finding in up to 90% of patients with idiopathic PD.1315 A recent prospective study on a cohort of patients with different types of parkinsonism has suggested a sensitivity of 90.7% and a specificity of 82.4% of midbrain hyperechogenicity on TCS for a diagnosis of idiopathic PD (iPD).22

In this study, only 1 (9.1%) of the SWEDD patients was found to have midbrain hyperechogenicity. In our PD group, we detected midbrain hyperechogenicity in 82.5%. This is in line with previous studies that reported midbrain hyperechogenicity in PD patients.13 The overall diagnostic accuracy of TCS in distinguishing PD from SWEDD was 85%.

Observer bias is unlikely to explain these different rates, because measurements of echogenicity were performed by an experienced sonographer, who was not involved in the clinical care or assessment of the patients and was kept blinded for their imaging findings as well as for their clinical presentation. Furthermore, SWEDD patients entered the study because of the presence of clinical signs suggestive of PD, making the distinction between the groups during a brief examination with the patient lying supine very unlikely.

The present study provides further evidence that most SWEDD patients do not have PD because their midbrain echogenicity was in the same range as in control subjects, and therefore SWEDDs and PD most likely have a different underlying pathophysiology. The normal DAT-SPECT scans in patients with suspected PD prompted us to seek for alternative diagnoses, and on follow-up, new working diagnoses included adult-onset dystonic tremor (n = 6), essential tremor (n = 4), psychogenic parkinsonism (n = 2), atypical tremor (n = 1), and vascular parkinsonism (n = 1).

Recent studies found that the extent of hyperechogenicity did not correlate with the degeneration of presynaptic dopaminergic nerve terminals in patients with PD, concluding that hyperechogenicity and degeneration of presynaptic dopaminergic nerve terminals exist independently from each other and may reflect different pathomechanisms.20, 23 Midbrain hyperechogenicity in PD seems to be a stable marker that does not change in the course of the disease.24

TCS is a commonly available, inexpensive, and noninvasive method without exposure to radiation, but its application may be limited because of an inadequate acoustic temporal bone window, particularly in older subjects. In this study, 15.2% of subjects did not have a sufficient bone window. This is in line with previous studies showing that in approximately 15% of subjects, midbrain structures are not assessable by TCS.13, 25

In the present study, the sensitivity of midbrain hyperechogenicity on TCS for a diagnosis of iPD was 83% and the specificity was 90.9%, respectively. In patients with suspected PD, hyperechogenicity indicates a high probability of PD, with a positive predictive value (PPV) of 93.3%.

The negative predictive value (NPV) for the diagnosis of SWEDD was 76.9%, indicating that absence of hyperechogenicity would strengthen the indication for DAT imaging.


Conclusions

We conclude that TCS is useful to distinguish patients with PD from patients with SWEDD and can provide additional information in patients presenting with inconclusive parkinsonian symptoms.


Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique.

H.S.: 1A, 1B, 1C, 2A, 2C, 3A

P.S.: 1A, 1B, 1C, 3A, 3B

A.D.: 1B, 1C, 3B

L.S.-M.: 1B, 1C, 3B

P.K.: 1B, 1C, 3B

K.S.: 1A, 1C, 2A, 2B, 3B

J.D.: 1C, 3B

M.J.E.: 1A, 1B, 3B

A.J.L.: 1A, 1B, 2C, 3B

W.P.: 1A, 1B, 1C, 2C, 3B

K.P.B.: 1A, 1B, 1C, 3B

Financial Disclosures: P.S. received speaker honoraria from Boehringer Ingelheim and Novartis and funding for travel to congresses from Boehringer Ingelheim, Ipsen, GlaxoSmithKline (GSK), Novartis, UCB, and Merck. A.D. has been employed by UCL/University College London Hospitals (UCLH). L.S.-M. has received honoraria from Teva Lundbeck; has been awarded grants from Parkinson's UK, UCB, Genus, and Abbott; and has been employed by Reta Lila Weston Trust for Medical Research, UCL. P.K. received financial support to attend meetings from Boehringer-Ingelheim, GSK, UCB, Bayer, and Novartis pharmaceutical companies. K.S. has received honoraria from AOP Orphan Pharmaceuticals AG, Boehringer Ingelheim, and Lundbeck and has been awarded grants from Medical University Innsbruck and Oesterreichische Nationalbank. M.J.E. has received honoraria from UCB; has been awarded grants from the National Institutes for Health Research Clinician Scientist Fellowship and Parkinson's UK; has been employed by UCL; and receives royalties from the Oxford University Press. A.J.L. has held a consultancy with Genus; has served on the advisory boards of Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira, and Roche; has received honoraria from Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira, and Roche; has been awarded grants from PSP Association, Weston Trust-The Reta Lila Howard Foundation; and has been employed by UCL/UCLH. W.P. has received consultancy and lecture fees from AstraZeneca, Teva, Novartis, GSK, Boehringer Ingelheim, UCB, Orion Pharma, Merck Serono, and Solvay-Abbott in relation to clinical drug development programs for PD; has been awarded an AstraZeneca grant (2009–2012); and has received royalties from Oxford University press and Wiley-Blackwell. K.P.B. received funding for travel from GSK, Orion Corporation, Ipsen, and Merz Pharmaceuticals, LLC; serves on the editorial boards of Movement Disorders and Therapeutic Advances in Neurological Disorders; received royalties from Oxford University Press; received speaker honoraria from GSK, Ipsen, Merz Pharmaceuticals, LLC, and Sun Pharmaceutical Industries Ltd.; received research support from Ipsen and from the Halley Stewart Trust through Dystonia Society UK as well as the Wellcome Trust MRC strategic neurodegenerative disease initiative award (ref. no.: WT089698).


References
1. Whone AL,Watts RL,Stoessl AJ,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REALPET studyAnn NeurolYear: 2003549310112838524
2. Marek K,Seibyl J. Beta-CIT scans without evidemce of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-cit study: long-term imaging assessmentNeurologyYear: 200360Suppl 1A293
3. Marshall VL,Reininger CB,Marquardt M,et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECTMov DisordYear: 20092450050819117369
4. Fahn S,Oakes D,Shoulson I,et al. Parkinson Study GroupLevodopa and the progression of Parkinson's diseaseN Engl J MedYear: 20043512498250815590952
5. Marek K,Jennings D,Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA studyNeurologyYear: 200564Suppl 1A274
6. Schwingenschuh P,Ruge D,Edwards MJ,et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological studyMov DisordYear: 20102556056920131394
7. Schneider SA,Edwards MJ,Mir P,et al. Patients with adultonset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs)Mov DisordYear: 2007222210221517712858
8. Bain PG. Dystonic tremor presenting as parkinsonism: long-term follow-up of SWEDDsNeurologyYear: 2009721443144519380706
9. Newman EJ,Breen K,Patterson J,Hadley DM,Grosset KA,Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of ScotlandMov DisordYear: 2009242379238519890985
10. Silveira-Moriyama L,Schwingenschuh P,O'Donnell A,et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs)J Neurol Neurosurg PsychiatryYear: 20098074474819276101
11. Mian OS,Schneider SA,Schwingenschuh P,Bhatia KP,Day BL. Gait in SWEDDs patients: comparison with Parkinson's disease and healthy controlsMov DisordYear: 2011261266127321442658
12. Bajaj NP,Gontu V,Birchall J,Patterson J,Grosset DG,Lees AJ. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video studyJ Neurol Neurosurg PsychiatryYear: 2010811223122820547625
13. Berg D,Godau J,Walter U. Transcranial sonography in movement disordersLancet NeurolYear: 200871044105518940694
14. Becker G,Seufert J,Bogdahn U,Reichmann H,Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real time sonographyNeurologyYear: 1995451821847824114
15. Berg D,Siefker C,Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findingsJ NeurolYear: 200124868468911569897
16. Berg D,Becker G,Zeiler B,et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasoundNeurologyYear: 1999531026103110496262
17. Berg D,Seppi K,Behnke S,et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older personsArch NeurolYear: 20116893293721747034
18. Stockner H,Iranzo A,Seppi K,et al. SINBAR (Sleep Innsbruck Barcelona) GroupMidbrain hyperechogenicity in idiopathic REM sleep behavior disorderMov DisordYear: 20092490690919205070
19. Iranzo A,Lomeña F,Stockner H,et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective studyLancet NeurolYear: 201091070107720846908
20. Spiegel J,Hellwig D,Möllers MO,et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's diseaseBrainYear: 20061291188119316513685
21. Seppi K,Scherfler C,Donnemiller E,et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysisArch NeurolYear: 2006631154116016908744
22. Gaenslen A,Unmuth B,Godau J,et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded studyLancet NeurolYear: 2008741742418394965
23. Doepp F,Plotkin M,Siegel L,et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremorMov DisordYear: 20082340541018067184
24. Berg D,Merz B,Reiners K,Naumann M,Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's diseaseMov DisordYear: 20052038338515486999
25. Stockner H,Seppi K,Kiechl S,et al. Assessment of the feasibility of midbrain sonography in a population-based studyMov DisordYear: 200722Suppl 16S146

Figures

[Figure ID: fig01]
FIG. 1 

Significantly increased area of midbrain echogenicity in the PD group compared with the SWEDD group (P < 0.001) (broken line: value set at 0.20 cm2 to define hyperechogenicity).



Tables
[TableWrap ID: tbl1] Table 1 

Demographic data, clinical data, TCS results of study patients, and diagnostic accuracy of midbrain hyperechogenicity for the differential diagnosis of PD versus SWEDD


Demographic and Clinical Data PD Patients SWEDD Patients PD Versus SWEDD
Patients, n 19 14
Female/male, n 7:12 7:7 0.497
Age, years (mean ± SD) 63.3. ± 7.5 68.2 ± 10.8 0.130
Age at onset, years (mean ± SD) 55.4 ± 11.8 56.3 ± 11.8 0.830
Disease duration, years (mean ± SD) 7.5 ± 7.2 14.9 ± 11.3 0.030*
DAT-SPECT after disease onset, years (mean ± SD) 7.2 ± 9.3 7.5 ± 7.9 0.900
Sufficient bone window, n (%) 17 (89.5) 11 (78.5) 0.630
Midbrain hyperechogenicity, n (%) 14 (82.5) 1 (9.1) <0.001*
UPDRS motor score, mean ± SD 18 ± 10 10.8 ± 3.7 0.020*
Sensitivity, % 82.4 (58.2–94.6)
Specificity, % 90.9 (60.1–99.9)
PPV, % 93.3 (68.2–99.9)
NPV, % 76.9 (49.1–92.5)
Overall accuracy, % 85.7 (67.9–94.9)
Likelihood ratio 9.06
TP, n 14
FP, n 1
FN, n 3
TN, n 10

Data in parentheses are the confidence intervals.

*Significance level: P < 0.05.

Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative.



Article Categories:
  • Brief Reports

Keywords: transcranial sonography, SWEDD, Parkinson's disease, hyperechogenicity.

Previous Document:  Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic...
Next Document:  A quantum-mechanical description of ion motion within the confining potentials of voltage-gated ion ...